Describe healthcare conditions, costs, and services received by DM patients versus matched non-DM controls (MCs) 1 year before confirmed DM diagnosis

Objectives

- Describe healthcare conditions, costs, and services received by DM patients versus matched non-DM controls (MCs) 1 year before confirmed DM diagnosis

Methods

- Retrospective database analysis to compare conditions, costs, and services of DM patients versus those of MCs
  - Database: IQVIA US PharMetrics® Plus
  - Time frame: January 2010 through March 2021
- The DM cohort is defined as having ≥2 DM claims ≥30 days apart
  - Claims identified by International Classification of Disease Ninth Revision (ICD-9) code 359.21 and Tenth Revision (ICD-10) code G71.11, which does not differentiate between DM subtypes
- The first diagnosis date was used for the index date
- DM patients were matched to a 5% random sample of eligible non-DM controls
  - Matching was done using R’s Matchit procedure, with nearest neighbor matching (exact matching on month of index date)
  - Cohorts were matched (5-MC:1-DM) on index month and baseline age, region, gender, plan, and payer type
- All subjects (patients and MCs) had a minimum of 12 months of continuous data prior to their index date
  - Because our focus was on the events preceding diagnosis, the index date was not included in the 1-year pre-index evaluation period
- Healthcare conditions, costs, and services used during the 12 months before each subject’s index date were compared using 283 US Agency for Healthcare Research & Quality (AHRQ) comorbidity categories
- Comparisons were made using t-tests for continuous variables and chi-square tests for discrete variables
- Total per member per year (PMPY) direct medical and prescription (Rx) costs were calculated for both DM and MC cohorts
- All costs were inflation adjusted using the US Bureau of Labor Statistics Consumer Price Index (CPI) for December 2020
  - Medical claims used the medical cost CPI and prescription claims used the prescription cost CPI

Background

- DM is a rare, dominantly inherited, monogenic, multisystem disease that causes myotonia, progressive muscle weakness, and atrophy, along with respiratory, gastrointestinal, cardiac, and central nervous system dysfunction, which significantly impacts quality of life
- There are two major types of DM (type 1 and type 2)
- Patients experience significant physical limitations, pain, fatigue, and a negative impact on wellbeing
- Currently, there is no cure or targeted treatment for DM
- Limited literature exists to quantify the burden of disease prior to diagnosis

Sponsorship

This poster is sponsored by Avidity Biosciences

Abbreviations

- AHRQ, Agency for Healthcare Research and Quality; CPI, Consumer Price Index; DM, myotonic dystrophy; ICD, International Classification of Disease; MC, matched control; PMPY, per member per year; Rx, prescription; SD, standard deviation.

References

Prevalence of Healthcare Conditions and Services Used by Patients with Myotonic Dystrophy (DM1 and DM2) Prior to Diagnosis: a Real-World Data Analysis

John W. Day¹, Kathryn A. Munoz², Richard A. Brook³, Bradley McEvoy², Mark C. Stahl², Kelly DiTrapani², Nathan L. Kleinman³, Chao-Yin Chen², Li-Jung Tai²

¹Stanford University Medical Center; ²Avidity Biosciences, Inc.; ³Better Health Worldwide. All authors have met authorship criteria.

## Results

- We identified 1,694 DM patients and 8,470 MCs
  - There were no significant differences between cohorts in descriptive characteristics (Table 1)
  - The cohorts had significant ($p<0.0001$) pre-index differences for the Charlson Comorbidity Index:
    - Mean scores were 0.82 (SD 1.51) for DM patients versus 0.44 (SD 1.19) for MCs
    - Percent of patients with values >1 was 19.1% for DM patients versus 9.7% for MCs
- Overall, compared with MCs:
  - **Conditions**: 160 out of 283 AHRQ categories had significantly higher pre-index use in DM patients (top categories by difference shown in Figure 1). One category had significantly greater use in MCs
  - **Costs**: 45 AHRQ categories had significantly different pre-index costs between cohorts (40 higher for DM; 5 higher for MCs). The top AHRQ categories by cost difference are shown in Figure 2
  - **Services**: 77 AHRQ categories had a significantly different number of pre-index services between cohorts (76 higher for DM; 1 higher for MCs). The top AHRQ categories by difference in the number of services are shown in Figure 3
- DM patients’ annual PMPY total cost, days of service, and PMPY services requiring healthcare are shown in Table 2

## Abbreviations

AHRQ, Agency for Healthcare Research and Quality; CPI, Consumer Price Index; DM, myotonic dystrophy; ICD, International Classification of Disease; MC, matched control; PMPY, per member per year; Rx, prescription; SD, standard deviation.

### Table 1. Age, US Region, Insurance, and Payer Type Were Similar for DM Patients and MCs

<table>
<thead>
<tr>
<th>Descriptive Characteristics</th>
<th>DM Patients (N=1,694)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender, % female</td>
<td>50.5%</td>
</tr>
<tr>
<td>Age, mean (SD) years</td>
<td>43.4 (18.1)</td>
</tr>
<tr>
<td>Age, years</td>
<td></td>
</tr>
<tr>
<td>&lt;18</td>
<td>10.8%</td>
</tr>
<tr>
<td>≥18 to &lt;35</td>
<td>19.3%</td>
</tr>
<tr>
<td>≥35 to &lt;45</td>
<td>18.2%</td>
</tr>
<tr>
<td>≥45 to &lt;55</td>
<td>20.1%</td>
</tr>
<tr>
<td>≥55 to &lt;65</td>
<td>23.0%</td>
</tr>
<tr>
<td>≥65</td>
<td>8.6%</td>
</tr>
<tr>
<td>US region</td>
<td></td>
</tr>
<tr>
<td>South</td>
<td>30.5%</td>
</tr>
<tr>
<td>Midwest</td>
<td>28.5%</td>
</tr>
<tr>
<td>Northeast</td>
<td>20.8%</td>
</tr>
<tr>
<td>West</td>
<td>18.5%</td>
</tr>
<tr>
<td>Unknown</td>
<td>1.7%</td>
</tr>
</tbody>
</table>

There were no significant differences between DM patients and MCs
Prevalence of Healthcare Conditions and Services Used by Patients with Myotonic Dystrophy (DM1 and DM2) Prior to Diagnosis: a Real-World Data Analysis

John W. Day1, Kathryn A. Munoz2, Richard A. Brook3, Bradley McEvoy2, Mark C. Stahl2, Kelly DiTrapani2, Nathan L. Kleinman3, Chao-Yin Chen2, Li-Jung Tai2
1Stanford University Medical Center; 2Avidity Biosciences, Inc.; 3Better Health Worldwide. All authors have met authorship criteria.

Figure 1. Prior to Diagnosis, DM Patients had Higher Absolute Differencesa in Prevalence for 160 AHRQ Categories vs MCs

Figure 2. Prior to Diagnosis, DM Patients had Higher Costs in AHRQ Categories of “Other Nervous System Disorders”, “Respiratory Failure, Insufficiency, Arrest”, “Septicemia”, “Other Connective Tissue Disorders”, and “Other Gastrointestinal Disorders” versus MCs

Abbreviations
AHRQ, Agency for Healthcare Research and Quality; CPI, Consumer Price Index; DM, myotonic dystrophy; ICD, International Classification of Disease; MC, matched control; PMPY, per member per year; Rx, prescription; SD, standard deviation.

Sponsorship
This poster is sponsored by Avidity Biosciences

*Sponsorship
This poster is sponsored by Avidity Biosciences

*All differences between cohorts p<0.000177 (threshold for multiple comparisons [0.05/283 comparisons])

*p<0.000177 (threshold for multiple comparisons [0.05/283 comparisons])
Prevalence of Healthcare Conditions and Services Used by Patients with Myotonic Dystrophy (DM1 and DM2) Prior to Diagnosis: a Real-World Data Analysis

John W. Day1, Kathryn A. Munoz2, Richard A. Brook3, Bradley McEvoy2, Mark C. Stahl2, Kelly DiTrapani2, Nathan L. Kleinman3, Chao-Yin Chen2, Li-Jung Tai2
1Stanford University Medical Center; 2Avidity Biosciences, Inc.; 3Better Health Worldwide. All authors have met authorship criteria.

Conclusions

- The journey to a DM diagnosis encounters a higher prevalence of services and costs associated with care of various nervous system disorders, connective tissue disorders, and respiratory conditions, as indicated by analysis of AHRQ and PMPY, respectively
  - This is consistent with the notion that the DM diagnosis is complex, and that symptom management on the journey to diagnosis contributes to the cost and burden of DM to patients and society
  - Identifying patterns of care prior to diagnosis of DM may support earlier diagnosis
- Based on the high unmet need, Avidity Biosciences is investigating AOC 1001 for the potential treatment of myotonic dystrophy type 1
- Future research is needed to investigate changes in AHRQ condition categories that occur after diagnosis and the patterns of concomitant therapy preceding diagnosis

Sponsorship
This poster is sponsored by Avidity Biosciences

Abbreviations
AHRQ, Agency for Healthcare Research and Quality; CPI, Consumer Price Index; DM, myotonic dystrophy; ICD, International Classification of Disease; MC, matched control; PMPY, per member per year; Rx, prescription; SD, standard deviation.